The European First Episode Schizophrenia Trial (EUFEST): comparison of outcome in first episode schizophrenia with different low dose antipsychotic drug regimens.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 28 Oct 2015

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Amisulpride (Primary) ; Haloperidol (Primary) ; Olanzapine (Primary) ; Quetiapine (Primary) ; Ziprasidone (Primary)
Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
Focus Pharmacodynamics; Therapeutic Use
Acronyms EUFEST

01 Sep 2015 Results presented at the 28th Annual Congress of the European College of Neuropsychopharmacology
28 Aug 2010 Subgroup analysis presented at the 23rd Annual Congress of the European College of Neuropsychopharmacology.
01 Dec 2009 Primary endpoints response rate and remission rate on the 'Positive and Negative Syndrome Scale' have been met for amisulpride, olanzapine and ziprasidone versus haloperidol.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com